PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017
PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck
PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017
PDL BioPharma to Present at the Oppenheimer 27th Annual Healthcare Conference
PDL BioPharma to Present at Two Upcoming Investor Conferences